Literature DB >> 32494988

Impact of initial midline shift in glioblastoma on survival.

Johannes Wach1, Motaz Hamed2, Patrick Schuss2, Erdem Güresir2, Ulrich Herrlinger3, Hartmut Vatter2, Matthias Schneider2.   

Abstract

The impact of midline shift (MLS) on long-term survival and progression in glioblastoma (GBM) is unknown. The objective of this study was to analyze the influence of mass effect on survival and progression with consideration of the patient demographics, tumor morphology, operative techniques, molecular pathology, and postoperative treatment. One hundred ninety-eight patients with GBM were analyzed retrospectively. Both MLS groups (< or ≥ 10 mm) were compared with regard to survival, progression-free survival (PFS), and postoperative course of Karnofsky Performance Status (KPS). A two-sided Fisher exact test showed no statistically significant differences in the confounders between the low- and high-MLS groups. The median survival was 18.0 months (95% confidence interval (CI) = 15.3-20.7) in the low-MLS group (n = 173) and 9.0 months (95% CI = 4.8-13.2) in the high-MLS group (n = 25) (p = 0.045). In the high-MLS group, 59.1% (13/22) with an initially high MLS had a KPS of less than 70% after 3 months, whereas 20.5% of the low-MLS group had a KPS of less than 70% (p < 0.001). Binary logistic regression analysis including the O-6-methylguanine-DNA methyltransferase (MGMT) status, extent of resection, baseline KPS, and MIB-I index showed low MLS as the only predictor for survival at 12 months (p = 0.046, odds ratio (OR) = 2.70, 95% CI = 1.0-7.2). Median PFS was 6.0 months in the high-MLS group and 9.0 months in the low-MLS group (log-rank test; p = 0.08). An initial midline shift of 10 mm or greater seems to be an imaging characteristic that independently predicts the survival in glioblastoma.

Entities:  

Keywords:  Glioblastoma; Mass effect; Midline shift; Survival

Year:  2020        PMID: 32494988     DOI: 10.1007/s10143-020-01328-w

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  33 in total

1.  Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.

Authors:  Marianne Labussière; Blandine Boisselier; Karima Mokhtari; Anna-Luisa Di Stefano; Anais Rahimian; Marta Rossetto; Pietro Ciccarino; Olivier Saulnier; Rosina Paterra; Yannick Marie; Gaetano Finocchiaro; Marc Sanson
Journal:  Neurology       Date:  2014-08-22       Impact factor: 9.910

2.  Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance.

Authors:  Daniela Kuhnt; Andreas Becker; Oliver Ganslandt; Miriam Bauer; Michael Buchfelder; Christopher Nimsky
Journal:  Neuro Oncol       Date:  2011-09-12       Impact factor: 12.300

3.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

Authors:  M Lacroix; D Abi-Said; D R Fourney; Z L Gokaslan; W Shi; F DeMonte; F F Lang; I E McCutcheon; S J Hassenbusch; E Holland; K Hess; C Michael; D Miller; R Sawaya
Journal:  J Neurosurg       Date:  2001-08       Impact factor: 5.115

4.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

5.  Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis.

Authors:  Kathleen R Lamborn; Susan M Chang; Michael D Prados
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

6.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Authors:  Marc Sanson; Yannick Marie; Sophie Paris; Ahmed Idbaih; Julien Laffaire; François Ducray; Soufiane El Hallani; Blandine Boisselier; Karima Mokhtari; Khe Hoang-Xuan; Jean-Yves Delattre
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 8.  Long-term survival with glioblastoma multiforme.

Authors:  Dietmar Krex; Barbara Klink; Christian Hartmann; Andreas von Deimling; Torsten Pietsch; Matthias Simon; Michael Sabel; Joachim P Steinbach; Oliver Heese; Guido Reifenberger; Michael Weller; Gabriele Schackert
Journal:  Brain       Date:  2007-09-04       Impact factor: 13.501

9.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.

Authors:  Jeanette E Eckel-Passow; Daniel H Lachance; Annette M Molinaro; Kyle M Walsh; Paul A Decker; Hugues Sicotte; Melike Pekmezci; Terri Rice; Matt L Kosel; Ivan V Smirnov; Gobinda Sarkar; Alissa A Caron; Thomas M Kollmeyer; Corinne E Praska; Anisha R Chada; Chandralekha Halder; Helen M Hansen; Lucie S McCoy; Paige M Bracci; Roxanne Marshall; Shichun Zheng; Gerald F Reis; Alexander R Pico; Brian P O'Neill; Jan C Buckner; Caterina Giannini; Jason T Huse; Arie Perry; Tarik Tihan; Mitchell S Berger; Susan M Chang; Michael D Prados; Joseph Wiemels; John K Wiencke; Margaret R Wrensch; Robert B Jenkins
Journal:  N Engl J Med       Date:  2015-06-10       Impact factor: 176.079

10.  Glioblastoma in Patients over 70 Years of Age.

Authors:  Uros Smrdel; Marija Skoblar Vidmar; Ales Smrdel
Journal:  Radiol Oncol       Date:  2018-02-25       Impact factor: 4.214

View more
  6 in total

1.  Red Blood Cell Distribution Width to Platelet Count Ratio Facilitates Preoperative Prediction of Recurrence in Surgically Treated Chronic Subdural Hematoma.

Authors:  Ági Güresir; Christoph Coch; Annkristin Heine; Elvira Mass; Tim Lampmann; Hartmut Vatter; Markus Velten; Marie-Therese Schmitz; Erdem Güresir; Johannes Wach
Journal:  Front Neurol       Date:  2022-05-11       Impact factor: 4.086

2.  Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma.

Authors:  Johannes Wach; Ági Güresir; Motaz Hamed; Hartmut Vatter; Ulrich Herrlinger; Erdem Güresir
Journal:  Cancers (Basel)       Date:  2022-04-25       Impact factor: 6.575

3.  Quantification of Tissue Compression Identifies High-Grade Glioma Patients with Reduced Survival.

Authors:  Elies Fuster-Garcia; Ivar Thokle Hovden; Siri Fløgstad Svensson; Christopher Larsson; Jonas Vardal; Atle Bjørnerud; Kyrre E Emblem
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

4.  Modelling glioma progression, mass effect and intracranial pressure in patient anatomy.

Authors:  Jana Lipková; Bjoern Menze; Benedikt Wiestler; Petros Koumoutsakos; John S Lowengrub
Journal:  J R Soc Interface       Date:  2022-03-23       Impact factor: 4.118

5.  Butterfly glioblastoma: Clinical characteristics, treatment strategies and outcomes in a population-based cohort.

Authors:  Line Sagerup Bjorland; Kathinka Dæhli Kurz; Øystein Fluge; Bjørnar Gilje; Rupavathana Mahesparan; Hege Sætran; Anastasia Ushakova; Elisabeth Farbu
Journal:  Neurooncol Adv       Date:  2022-07-01

6.  Mean Platelet Volume/Platelet Count Ratio and Risk of Progression in Glioblastoma.

Authors:  Johannes Wach; Stefanos Apallas; Matthias Schneider; Johannes Weller; Patrick Schuss; Hartmut Vatter; Ulrich Herrlinger; Erdem Güresir
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.